Ugur Sahin

“A warm welcome to everyone joining us today. We have made good progress against our strategic milestones set out for 2026, reflecting our continued commitment to advancing our pipeline.”

“I believe it is important to note that this transition reflects the natural evolution of BioNTech from a pioneering research organization into a global biopharmaceutical company with multiple commercial products.”

“If BioNTech has grown, our vision has remained constant, translating science into survival. Cancer is a complex systems disease with heterogeneity across patients and variability within individual tumors.”

“As BioNTech has grown, our vision has remained constant, namely translating science into survival. Our focus is on oncology. Cancer remains a complex systems problem, varying between patients and further with an individual tumor.”

“As BioNTech has grown, our vision has remained constant, namely translating science into survival. We are building a global immunotherapy powerhouse, a fully integrated biopharmaceutical company with the science, scale, capabilities, and the aim to deliver multiple approved therapies and reach patients in need.”